---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-21-000935"
form_type: "8-K"
ticker: "TEVA"
cik: "0000818686"
company_name: "TEVA PHARMACEUTICAL INDUSTRIES LTD"
filed_at: "2021-07-28T23:59:59+00:00"
generated_at: "2026-06-30T01:54:54.953601+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Teva Q2 2021: Revenue $3.9B, GAAP EPS $0.19, Non-GAAP EPS $0.59; guides revenue lower

## Summary
- Revenue of $3.9B (up 1% YoY); GAAP diluted EPS $0.19 (vs $0.13 Q2 2020); Non-GAAP diluted EPS $0.59 (vs $0.55).
- Net debt reduced by $500M to $22.7B; operating cash flow $218M, free cash flow $625M.
- 2021 revenue outlook cut to $16.0-16.4B (prior $16.4-16.8B) citing COVID impact; all other guidance reaffirmed: adj. EBITDA $4.8-5.1B, EPS $2.50-2.70, FCF $2.0-2.3B.
- AUSTEDO sales grew YoY; AJOVY net sales $70M worldwide; Truxima US market share reached 25%.
- R&D expenses $248M (GAAP), increased 10% YoY, driven by respiratory, biosimilar projects.

## SEC filing metadata
- accession: 0001157523-21-000935
- form_type: 8-K
- ticker: TEVA
- cik: 0000818686
- company_name: TEVA PHARMACEUTICAL INDUSTRIES LTD
- filed_at: 2021-07-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818686/000115752321000935/0001157523-21-000935-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818686/000115752321000935/a52467373.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-21-000935
- JSON: https://secwatch.observer/filing/0001157523-21-000935.json
- Plain text: https://secwatch.observer/filing/0001157523-21-000935.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.